This is the approach explored here, using two of the leading malaria vaccine candidates, CSP and TRAP, and a commonly used murine model of malaria using Plasmodium berghei (30); murine models represent an inexpensive and useful way to examine vaccines in a preclinical setting before progression to human trials. This evidence concerns the gene DNAJC5 and malaria.